查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1586281

降膽固醇藥物市場：按疾病類型、藥物類別、分銷管道分類 - 全球預測 2025-2030

Cholesterol Lowering Drug Market by Disease Type (Cardiovascular Diseases, Hypercholesterolemia, Hyperlipidemia), Class of Drug (Cholesterol Absorption Inhibitors, Fibrates, Fixed-Dose Combinations), Distribution Channels - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年降膽固醇藥物市值為220億美元，預計2024年將達到238億美元，複合年成長率為8.30%，預計2030年將達到384.5億美元。

降膽固醇藥物市場是製藥業的重要組成部分，重點關注旨在降低血液膽固醇水平的藥物，主要針對低密度脂蛋白膽固醇，以預防心血管疾病。由於不良飲食、缺乏體力活動和老化等生活方式因素，全球範圍內膽固醇相關疾病的增加凸顯了對此類藥物的需求。應用範圍從對高風險族群的預防性治療到對已經患有心血管疾病的人群的干涉，最終用戶包括醫院、診所和治療慢性病的個人。該市場的成長主要受到高膽固醇症盛行率的增加、老年人口的擴大以及人們對心臟健康意識不斷增強的影響。

主要市場統計
基準年[2023] 220億美元
預測年份 [2024] 238億美元
預測年份 [2030] 384.5億美元
複合年成長率（%） 8.30%

然而，品牌藥物的高成本、潛在副作用和藥物依從性挑戰等限制因素可能會阻礙市場擴張。此外，替代療法和生活方式干涉措施的日益普及也帶來了競爭挑戰。儘管存在這些障礙，潛在的機會在於新型生技藥品和生物學名藥的開發、個人化醫療方法以及醫療保健可及性不斷改善的新興市場的擴張。為了抓住這些機會，鼓勵製藥公司投資下一代降膽固醇藥物的研發，並利用資料分析來制定個人化治療計畫。

創新可以集中於解決多種心血管危險因素的聯合治療和支持患者監測和依從性的數位健康技術。基因療法和營養食品的研究也有望成為突破性的治療方法。在未滿足的醫療需求和技術進步的推動下，市場競爭激烈，但充滿潛力。生物技術公司和研究機構之間的聯盟可以進一步加強藥物發現過程，與醫療保健提供者的策略聯盟可以提高患者參與度和市場滲透率。

市場動態：揭示快速發展的降膽固醇藥物市場的關鍵市場洞察

供需的動態交互作用正在改變降膽固醇藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 全球低密度脂蛋白膽固醇負擔增加
    • 患有膽固醇問題的老年人數量不斷增加
    • 吸菸和飲酒增加會增加高膽固醇的風險
  • 市場限制因素
    • 他汀類藥物的嚴重副作用導致橫紋肌溶解症
  • 市場機會
    • 政府投資加強衛生基礎設施
    • 藥物配方的開發和新治療方法的出現，包括PCSK9抑制劑的出現
  • 市場問題
    • 主要品牌學名藥的可用性和嚴格的核准流程

波特五力：駕馭降膽固醇藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解降膽固醇藥物市場的外部影響

外部宏觀環境因素在塑造降膽固醇藥物市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解降膽固醇藥物市場的競爭格局

降膽固醇藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV 定位矩陣降膽固醇藥物市場供應商的績效評估

FPNV定位矩陣是評估降膽固醇藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：制定降膽固醇藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對降膽固醇藥物市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球低密度脂蛋白膽固醇負擔增加
      • 患有膽固醇併發症的老年人增加
      • 吸菸和增加飲酒會增加高膽固醇的風險
    • 抑制因素
      • 他汀類藥物的嚴重副作用導致橫紋肌溶解症
    • 機會
      • 政府投資加強醫療基礎設施
      • 藥物組合的開發和新治療方法的出現，例如 PCSK9 抑制劑的出現
    • 任務
      • 領先品牌學名藥的可用性和嚴格的核准流程
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章降膽固醇藥物市場：依疾病類型

  • 介紹
  • 心血管疾病
  • 高膽固醇症
  • 高血脂症

第7章降膽固醇藥物市場：依藥物類型

  • 介紹
  • 膽固醇吸收抑制劑
  • 貝特類
  • 固定劑量組合
  • 離子交換樹脂
  • 新的降膽固醇藥物
  • PCSK9抑制劑
  • 他汀類藥物

第8章降膽固醇藥物市場：按分銷管道

  • 介紹
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第9章北美和南美降膽固醇藥物市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區降膽固醇藥物市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲降膽固醇藥物市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Amgen Inc.
  • Anant Pharmaceuticals Pvt. Ltd.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Covis Pharma GmbH
  • Daiichi Sankyo Co., Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Kowa Company, Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-4311CE1A338E

The Cholesterol Lowering Drug Market was valued at USD 22.00 billion in 2023, expected to reach USD 23.80 billion in 2024, and is projected to grow at a CAGR of 8.30%, to USD 38.45 billion by 2030.

The market for cholesterol-lowering drugs is a vital segment of the pharmaceutical industry, focusing on medications designed to reduce cholesterol levels in the blood, primarily targeting LDL cholesterol, to prevent cardiovascular diseases. The necessity for such drugs is underscored by the global rise in cholesterol-related conditions, driven by lifestyle factors such as poor diet, lack of exercise, and an aging population. Their application ranges from preventive treatments for at-risk individuals to interventions for those with existing cardiovascular issues, with end-users including hospitals, clinics, and individuals managing chronic conditions. Growth in this market is primarily influenced by the increasing prevalence of hypercholesterolemia, an expanding geriatric population, and heightened awareness of heart health.

KEY MARKET STATISTICS
Base Year [2023] USD 22.00 billion
Estimated Year [2024] USD 23.80 billion
Forecast Year [2030] USD 38.45 billion
CAGR (%) 8.30%

However, limitations such as high costs of branded medications, potential side effects, and medication adherence challenges can hinder market expansion. Moreover, the growing popularity of alternative therapies and lifestyle-based interventions presents a competitive challenge. Despite these obstacles, potential opportunities lie in the development of novel biologics and biosimilars, personalized medicine approaches, and expanding markets in emerging economies where healthcare access is improving. To seize these opportunities, pharmaceutical companies are advised to invest in R&D for next-generation cholesterol-lowering agents and leverage data analytics to develop personalized treatment plans.

Innovation could focus on combination therapies that address multiple cardiovascular risk factors, as well as digital health technologies that assist in patient monitoring and adherence. Research into gene therapy and nutraceuticals also offers promising avenues for breakthrough treatments. The nature of the market is increasingly competitive yet ripe with potential, driven by unmet medical needs and technological advancements. Collaborations between biotech firms and research institutions could further enhance drug discovery processes, while strategic alliances with healthcare providers could improve patient engagement and market penetration.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cholesterol Lowering Drug Market

The Cholesterol Lowering Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising burden of LDL cholesterol across the globe
    • Growing geriatric population with cholesterol complications
    • Increase in smoking and alcohol consumption escalate the risk of high cholesterol
  • Market Restraints
    • Severe side effects of statins causing rhabdomyolysis
  • Market Opportunities
    • Government investment toward the strengthening healthcare infrastructure
    • Development of drug formulation and emergence of new therapies such as emergence of PCSK9 inhibitors
  • Market Challenges
    • Availability of generic drugs of leading brands and stringent approvals process

Porter's Five Forces: A Strategic Tool for Navigating the Cholesterol Lowering Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cholesterol Lowering Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cholesterol Lowering Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cholesterol Lowering Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cholesterol Lowering Drug Market

A detailed market share analysis in the Cholesterol Lowering Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cholesterol Lowering Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cholesterol Lowering Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cholesterol Lowering Drug Market

A strategic analysis of the Cholesterol Lowering Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cholesterol Lowering Drug Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Anant Pharmaceuticals Pvt. Ltd., AstraZeneca PLC, Bristol-Myers Squibb Company, Covis Pharma GmbH, Daiichi Sankyo Co., Ltd., Dr. Reddy's Laboratories Ltd., Kowa Company, Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Cholesterol Lowering Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Cardiovascular Diseases, Hypercholesterolemia, and Hyperlipidemia.
  • Based on Class of Drug, market is studied across Cholesterol Absorption Inhibitors, Fibrates, Fixed-Dose Combinations, Ion Exchange Resins, Novel Cholesterol-Lowering Drugs, PCSK9 Inhibitors, and Statins.
  • Based on Distribution Channels, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising burden of LDL cholesterol across the globe
      • 5.1.1.2. Growing geriatric population with cholesterol complications
      • 5.1.1.3. Increase in smoking and alcohol consumption escalate the risk of high cholesterol
    • 5.1.2. Restraints
      • 5.1.2.1. Severe side effects of statins causing rhabdomyolysis
    • 5.1.3. Opportunities
      • 5.1.3.1. Government investment toward the strengthening healthcare infrastructure
      • 5.1.3.2. Development of drug formulation and emergence of new therapies such as emergence of PCSK9 inhibitors
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of generic drugs of leading brands and stringent approvals process
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cholesterol Lowering Drug Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Cardiovascular Diseases
  • 6.3. Hypercholesterolemia
  • 6.4. Hyperlipidemia

7. Cholesterol Lowering Drug Market, by Class of Drug

  • 7.1. Introduction
  • 7.2. Cholesterol Absorption Inhibitors
  • 7.3. Fibrates
  • 7.4. Fixed-Dose Combinations
  • 7.5. Ion Exchange Resins
  • 7.6. Novel Cholesterol-Lowering Drugs
  • 7.7. PCSK9 Inhibitors
  • 7.8. Statins

8. Cholesterol Lowering Drug Market, by Distribution Channels

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Cholesterol Lowering Drug Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cholesterol Lowering Drug Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cholesterol Lowering Drug Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. Anant Pharmaceuticals Pvt. Ltd.
  • 3. AstraZeneca PLC
  • 4. Bristol-Myers Squibb Company
  • 5. Covis Pharma GmbH
  • 6. Daiichi Sankyo Co., Ltd.
  • 7. Dr. Reddy's Laboratories Ltd.
  • 8. Kowa Company, Ltd.
  • 9. Merck & Co., Inc.
  • 10. Novartis AG
  • 11. Pfizer Inc.
  • 12. Sanofi
  • 13. Sun Pharmaceutical Industries Ltd.
  • 14. Teva Pharmaceutical Industries Ltd.
  • 15. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. CHOLESTEROL LOWERING DRUG MARKET RESEARCH PROCESS
  • FIGURE 2. CHOLESTEROL LOWERING DRUG MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CHOLESTEROL LOWERING DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CHOLESTEROL LOWERING DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CHOLESTEROL LOWERING DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CHOLESTEROL LOWERING DRUG MARKET DYNAMICS
  • TABLE 7. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HYPERLIPIDEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CHOLESTEROL ABSORPTION INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY FIBRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY FIXED-DOSE COMBINATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ION EXCHANGE RESINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY NOVEL CHOLESTEROL-LOWERING DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY STATINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 150. CHOLESTEROL LOWERING DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 151. CHOLESTEROL LOWERING DRUG MARKET, FPNV POSITIONING MATRIX, 2023